Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Blinded, Safety, Tolerability, and Pharmacokinetic Study of Single Doses of BIIB059 in Healthy Japanese Subjects

Trial Profile

A Blinded, Safety, Tolerability, and Pharmacokinetic Study of Single Doses of BIIB059 in Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs BIIB 059 (Primary)
  • Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 30 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2018 Planned End Date changed from 29 May 2018 to 12 Jun 2018.
    • 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top